Kinetics of maternally acquired anti-hepatitis A antibodies: Prediction of waning based on maternal or cord blood antibody levels

Vaccine

Volumn 31, Issue 11, 2013, Pages 1490-1495

  Brinkhof, Martin W G ^a,f   Mayorga, Orlando ^b   Bock, Jürgen ^c   Heininger, Ulrich ^d   Herzog, Christian ^e,g  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c University Children's Hospital ^*  (Germany)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^e CRUCELL HOLLAND BV   (Netherlands)

^f SWISS PARAPLEGIC RESEARCH   (Switzerland)

^g SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

Hepatitis A; Infants; Maternal antibodies; Placental transfer; Waning immunity

Indexed keywords

HEPATITIS A ANTIBODY; MATERNAL ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HEPATITIS A; HUMAN; KINETICS; MAJOR CLINICAL STUDY; MATERNAL BLOOD; NICARAGUA; PASSIVE IMMUNIZATION; PLACENTAL TRANSFER; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SAMPLING; SEROPREVALENCE; UMBILICAL CORD BLOOD;

EID: 84874435729     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.01.011     Document Type: Article

References (51)

1. Tapia-Conyer R., Santos J.I., Cavalcanti A.M., Urdaneta E., Rivera L., Manterola A., et al. Hepatitis A in Latin America: a changing epidemiologic pattern. Am J Trop Med Hyg 1999, 61:825-829.
2. World Health Organization WHO position paper on hepatitis A vaccines - June 2012. Wkly Epid Rec 2012, 87:261-276.
3. Wasley A., Fiore A., Bell B.P. Hepatitis A in the era of vaccination. Epidemiol Rev 2006, 28:101-111.
4. Dagan R., Leventhal A., Anis E., Slater P., Ashur Y., Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005, 294:202-210.
5. Wasley A., Samandari T., Bell B.P. Incidence of hepatitis A in the United States in the era of vaccination. JAMA 2005, 294:194-201.
6. Hendrickx G., Van Herck K., Vorsters A., Wiersma S., Shapiro C., Andrus J.K., et al. Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology. J Viral Hepatitis 2008, 15(Suppl. 2):1-15.
7. Piazza M., Safary A., Vegnente A., Soncini R., Pensati P., Sardo M., et al. Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme. Vaccine 1999, 17:585-588.
8. Dagan R., Amir J., Mijalovsky A., Kalmanovitch I., Bar-Yochai A., Thoelen S., et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J 2000, 19:1045-1052.
9. Kanra G., Yalçin S., Ceyhan M., Yurdakök K. Clinical trial to evaluate immunogenicity and safety of inactivated hepatitis A vaccination starting at 2-month-old children. Turk J Pediatr 2000, 42:105-108.
10. ®). Vaccine 2003, 21:4588-4592.
11. Lagos R., Munoz A., Dumas R., Pichon S., Zambrano B., Levine M., et al. Immunological priming of one dose of inactivated hepatitis A vaccine given during the first year of life in the presence of maternal antibodies. Vaccine 2003, 21:3730-3733.
12. Letson G.W., Shapiro C.N., Kuehn D., Gardea C., Welty T.K., Krause D.S., et al. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. J Pediatr 2004, 144:327-332.
13. Stojanov S., Liese J.G., Belohradsky B.H., Vandermeulen C., Hoppenbrouwers K., Van der Wielen M., et al. Administration of hepatitis A vaccine at 6 and 12 months of age concomitantly with hexavalent (DTaP-IPV-PRP∼T-HBs) combination vaccine. Vaccine 2007, 25:7549-7558.
14. Bell B.P., Negus S., Fiore E.A., Plotnik J., Dhotre K.B., Williams J., et al. Immunogenicity of an inactivated hepatitis A vaccine in infants and young children. Pediatr Infect Dis J 2007, 26:116-122.
15. Lieberman J.M., Marcy M., Partridge S., Ward J.I. Evaluation of HA vaccine in infants: effects of maternal antibodies on antibody response [Abstract 76]. Program and Abstracts of the 36th Annual Meeting of the Infectious Diseases Society of America, Denver, CO 1998, Infectious Diseases Society of America, Alexandria, VA, p. 38.
16. Burek V., Bacé A., Kacic M., Belosevic, Mravunac B. Prevalence of antibodies to hepatitis A virus among urban children aged 0-7 years in Yugoslavia. J Infect 1985, 10:71-75.
17. Ruiz-Gomez J., Bustamente-Calvillo E. Hepatitis A antibodies: prevalence and persistence in a group of Mexican children. Am J Epidemiol 1985, 121:116-119.
18. Willcox M.C., Andersson C., Olsson I. The postnatal decline in antibody to hepatitis A virus. Trans R Soc Trop Med Hyg 1985, 79:738.
19. Franzen C., Frösner G. Placental transfer of hepatitis A antibody. New Engl J Med 1981, 304:427.
20. Linder N., Karetnyi Y., Gidony Y., Dagan R., Ohel G., Levin E., et al. Decline of hepatitis A antibodies during the first 7 months of life in full-term and preterm infants. Infection 1999, 27:128-131.
21. Lieberman J.M., Chang S.-J., Partridge S., Hollister J.C., Kaplan K.M., Jensen E.H., et al. Kinetics of maternal hepatitis A antibody decay in infants: implications for vaccine use. Pediatr Infect Dis J 2002, 21:347-348.
22. De Silvestri A., Avanzini M.A., Terulla V., Zucca S., Polatti F., Belloni C. Decline of maternal hepatitis A virus antibody levels in infants. Acta Paediatr 2002, 91:882-884.
23. Darya A., Necmi A., Emre A., Akgün Y. Decline of maternal hepatitis A antibodies during the first 2 years of life in infants born in Turkey. Am J Trop Med Hyg 2005, 73:457-459.
24. Centers for Disease Control Prevention Prevention of hepatitis A through active or passive immunization. Morb Mortal Wkly Rep 2006, 55(RR-7):1-23.
25. Van Savage J., Decker M.D., Edwards K.M., Sell S.H., Karzon D.T. Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis 1990, 161:487-492.
26. Englund J.A., Glezen W.P., Thompson C., Anwaruddin R., Turner C.S., Siber G.R. Haemophilus influenzae type b-specific antibody in infants after maternal immunization. Pediatr Infect Dis J 1997, 16:1122-1130.
27. Cáceres V.M., Strebel P.M., Sutter R.W. Factors determining prevalence of maternal antibody to measles virus throughout infancy: a review. Clin Infect Dis 2000, 31:110-119.
28. Perez O.M., Morales W., Paniagua M., Strannegard O. Prevalence of antibodies to hepatitis A, B, C and E viruses in a healthy population in Leon, Nicaragua. Am J Trop Med Hyg 1996, 55:17-21.
29. Mayorga Perez O., Herzog C., Zellmeyer M., Loáisiga A., Frösner G., Egger M. Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial. J Infect Dis 2003, 188:671-677.
30. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, i:307-310.
31. Bradley E.L., Blackwood L.G. Comparing paired data: a simultaneous test of means and variances. Am Stat 1989, 43:234-235.
32. Gonçalves G., Cutts F.T., Hills M., Rebelo-Andrade H., Trigo F.A., Barros H. Transplacental transfer of measles and total IgG. Epidemiol Infect 1999, 122:273-279.
33. Hartter H.K., Oyedele O.I., Dietz K., Kreis S., Hoffman J.P., Muller C.P. Placental transfer and decay of maternally acquired antimeasles antibodies in Nigerian children. Pediatr Infect Dis J 2000, 19:635-641.
34. Linder N., Karetnyi Y., Gidony Y., et al. Placental transfer of hepatitis A antibodies in full term and pre-term infants. Pediatr Infect Dis J 1997, 16:245-247.
35. Simister N.E. Placental transport of immunoglobulin G. Vaccine 2003, 21:3365-3369.
36. Van den Berg J.P., Westerbeck E.A.M., Berbers G.A.M., van Gageldonk P.G., van der Klis F.R., van Elburg R.M. Transplacental transport of IgG antibodies specific for pertussis, diphtheria, tetanus, Haemophilus influenzae Type b, and Neisseria meningitidis Serogroup C is lower in preterm compared with term infants. Pediatr Infect Dis J 2010, 29:801-805.
37. Heininger U., Riffelmann M., Leineweber B., Wirsing von Koenig C.H. Maternally derived antibodies against Bordetella pertussis antigens toxin and filamentous hemagglutinin in preterm and full term newborns. Pediatr Infect Dis J 2009, 28:443-445.
38. Leuridan E., Hens N., Hutse V., Ieven M., Aerts M., Van Damme P. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. Br Med J 2010, 340:c1626.
39. Healy C.M., Baker C.J. Maternal immunization. Pediatr Infect Dis J 2007, 26:945-948.
40. Centers for Disease Control Prevention Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months - Advisory Committee on Immunization Practices (ACIP), 2011. Morb Mortal Wkly Rep 2011, 60(41):1424-1426.
41. Linder N., Karetnyi Y.V., Kuint J., Mendelson E. Symptomatic hepatitis A virus infection during the first year of life. Pediatr Infect Dis J 1995, 14:628-629.
42. Ciocca M., Moreira-Silva S.F., Alegria S., Galoppo M.C., Ruttiman R., Porta G., et al. Hepatitis A as an etiologic agent of acute liver failure in Latin America. Pediatr Infect Dis J 2007, 26:711-715.
43. WHO Collaborative Study Group on Oral Poliovirus Vaccine. Factors affecting the immunogenicity of oral poliovirus vaccine: prospective evaluation in Brazil and the Gambia. J Infect Dis 1995, 71:1097-1106.
44. Siegrist C.-A. Neonatal and early life vaccinology. Vaccine 2001, 19:3331-3346.
45. Hu Y., Wu G., Xu B., Zhou Z., Wang Z., Zhou Y.H. Influence of maternal antibody against hepatitis B surface antigen on immune response to hepatitis B vaccine in infants. Vaccine 2008, 26:6064-6067.
46. Siegrist C.-A. Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine 2003, 21:3406-3412.
47. Kim D., Huey D., Oglesbee M., Niewiesk S. Insights into the regulatory mechanism controlling the inhibition of vaccine-induced seroconversion by maternal antibodies. Blood 2011, 117:6143-6151.
48. Dagan R., Amir J., Livni G., Greenberg D., Abu-Abed J., Guy L., et al. Concomitant administration of a virosome-adjuvanted hepatitis A vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial. Pediatr Infect Dis J 2007, 26:787-793.
49. Kanra G., Yalcin S.S., Kara A., Ozmert E., Yurdakök K. Hepatitis A booster vaccine in children after infant immunization. Pediatr Infect Dis J 2002, 21:727-730.
50. Troisi C.L., Hollinger F.B., Krause D.S., Pickering L.K. Immunization of seronegative infants with hepatitis A vaccine (Havrix; SKB): a comparative study of two dosing schedules. Vaccine 1997, 15:1613-1617.
51. Fiore A.E., Shapiro C.N., Sabin K., Labonte K., Darling K., Culver D., et al. Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose. Pediatr Infect Dis J 2003, 22:354-359.